Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis
Age and Ageing · 2025
DOI: 10.1093/ageing/afaf219 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Age and Ageing, 2025. Verfasst von Catriona Reddin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Health Research Board Clinical Research Facility Galway, University of Galway, Galway, Ireland. Hauptthemen laut MEDLINE: Dementia, Hypolipidemic Agents, Cognition, Cognitive Dysfunction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background and objectives Lipid-lowering agents are effective in reducing cardiovascular risk, but their effect on cognitive impairment and dementia is uncertain. The aim of this meta-analysis was to determine whether lipid-lowering therapy, compared to control, was associated with a reduction in risk of dementia or cognitive impairment.
Methods
We performed a systematic review and meta-analysis of randomised controlled trials comparing lipid-lowering therapy to control that reported dementia or change in cognitive scores, adhering to the Cochrane Collaboration Guidelines. A random effects meta-analysis was used to estimate a pooled treatment-effect. The primary outcome measure was incident cognitive impairment or dementia.
Results
Twenty randomised controlled trials were eligible for inclusion, 15 trials (n = 139 169 participants) reported dementia or cognitive impairment on follow-up (primary outcome) and nine trials (n = 32 370) reported on change in cognitive score. The mean (SD) age of trial participants was 65.4 (5.06) years in the intervention arm and 65.4 (5.03) in the control arm. Lipid-lowering therapy compared with control was not associated with a significant reduction in dementia or cognitive impairment (1.33% vs 1.36% over a mean trial follow-up of 34.5 months; Odds Ratio, 0.96; 95% CI, 0.74–1.26). Heterogeneity was moderate (I2 = 37.6%). There was no significant association amongst drug classes (Statin; OR 0.90; 95% CI, 0.67–1.21, PCSK9 inhibitor: OR 1.77; 95% CI, 0.46–6.83, Other: OR 0.85; 0.61–1.17).
Discussion
In this meta-analysis of over 100 000 participants, lipid-lowering therapy was not significantly associated with a lower risk of incident cognitive impairment or dementia. This meta-analysis provides evidence to support the safety of lipid-lowering therapy on cognitive health, however, does not provide evidence of risk reduction of incident cognitive impairment or dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Health Research Board Clinical Research Facility Galway, University of Galway, Galway, Ireland.
- Department of Medicine, Galway University Hospitals -Newcastle Road Galway, Galway, Ireland.
- University College London - MRC Unit for Lifelong Health and Ageing, 33 Bedford Place, London WC1B 5JU.
ORCID-Profile: Catriona Reddin, Michelle Canavan, Daniel H J Davis
Zitieren
APA
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O'Donnell, M. (2025). Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis. Age and Ageing. https://doi.org/10.1093/ageing/afaf219
Vancouver
Reddin C, Stankard A, Chan KY, Krewer F, Judge C, Canavan M, et al. Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis. Age and Ageing. 2025. doi:10.1093/ageing/afaf219
BibTeX
@article{Reddin2025,
author = {Reddin, Catriona and Stankard, Aidan and Chan, Kei Yen and Krewer, Finn and Judge, Conor and Canavan, Michelle and Davis, Daniel H J and O'Donnell, Martin},
title = {Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis},
journal = {Age and Ageing},
year = {2025},
doi = {10.1093/ageing/afaf219}
}
EUVIMED